CD34 and sickle cell disease: While extrapolated cell doses from human HPC-A products manufactured in this study would easily achieve this threshold, CD34+ cell numbers from BM products would be more clinically useful for children, requiring further optimization for adult patient populations for whom BM is the desired CD34+ cell source (for example, sickle cell disease).